GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spago Nanomedical AB (OSTO:SPAGO) » Definitions » Debt-to-Asset

Spago Nanomedical AB (OSTO:SPAGO) Debt-to-Asset : 0.00 (As of Mar. 2025)


View and export this data going back to 2012. Start your Free Trial

What is Spago Nanomedical AB Debt-to-Asset?

Spago Nanomedical AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was kr0.00 Mil. Spago Nanomedical AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was kr0.00 Mil. Spago Nanomedical AB's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2025 was kr30.29 Mil. Spago Nanomedical AB's debt to asset for the quarter that ended in Mar. 2025 was 0.00.


Spago Nanomedical AB Debt-to-Asset Historical Data

The historical data trend for Spago Nanomedical AB's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spago Nanomedical AB Debt-to-Asset Chart

Spago Nanomedical AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Spago Nanomedical AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Spago Nanomedical AB's Debt-to-Asset

For the Biotechnology subindustry, Spago Nanomedical AB's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Spago Nanomedical AB's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Spago Nanomedical AB's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Spago Nanomedical AB's Debt-to-Asset falls into.


;
;

Spago Nanomedical AB Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Spago Nanomedical AB's Debt-to-Asset for the fiscal year that ended in Dec. 2024 is calculated as

Spago Nanomedical AB's Debt-to-Asset for the quarter that ended in Mar. 2025 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Spago Nanomedical AB  (OSTO:SPAGO) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Spago Nanomedical AB Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Spago Nanomedical AB's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Spago Nanomedical AB Business Description

Traded in Other Exchanges
N/A
Address
Scheelevagen 22, Lund, SWE, SE-223 63
Spago Nanomedical AB is a nanomedicine company in the field of cancer diagnosis and treatment. The company's product includes SpagoPix and Tumorad. The SpagoPix product aims to improve cancer diagnosis with magnetic resonance imaging through the previous detection of tumors and metastases. The Tumorad products focus on the development of a completely new form of radionuclide therapy for tumor-selective radiation therapy of cancer. The company's development projects are based on a platform of polymeric materials with various properties for the precise diagnosis and treatment of life-threatening and debilitating diseases.

Spago Nanomedical AB Headlines

No Headlines